SARS-CoV-2 Spike S1 RBD-ACE2 Bin

Confirm delete?

SARS-CoV-2 Spike S1 RBD-ACE2 Binding Cellular Imaging Assay Kit

Zoom

Cat No: 701970

Assay Kits - Cell-Based Assays

Cayman’s SARS-CoV-2 Spike S1 RBD-ACE2 Binding Cellular Imaging Assay Kit provides a sensitive and unique imaging platform for identifying novel modulators of SARS-CoV-2 spike S1 RBD and ACE2 binding. This assay uses Cayman’s proprietary reverse transf...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

CoV2 ACE 2 coronavirus covid-19

Product Overview:
Cayman’s SARS-CoV-2 Spike S1 RBD-ACE2 Binding Cellular Imaging Assay Kit provides a sensitive and unique imaging platform for identifying novel modulators of SARS-CoV-2 spike S1 RBD and ACE2 binding. This assay uses Cayman’s proprietary reverse transfection platform to express human ACE2 on the surface of HEK293T/17 cells for binding by a recombinant rabbit Fc-tagged SARS-CoV-2 spike S1 RBD protein as a model of SARS-CoV-2 cellular infection.{55525} Binding of the spike S1 RBD to ACE2 is detected with a DyLight™ 550-conjugated anti-rabbit Fc antibody by fluorescence imaging. Inhibition of spike S1 RBD binding to ACE2 results in decreased fluorescence. A positive control neutralizing antibody is included to inhibit the binding between the SARS-CoV-2 spike S1 RBD and ACE2.

Size	1 ea
Shipping	dry ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.